Cargando…
Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen
We evaluate the prognostic value of chemotherapy and other prognostic factors on overall survival among colon patients with deficient mismatch repair (dMMR), and determine the optimum time to start chemotherapy after surgery. Data of 306 colon cancer patients with dMMR who received radical surgery w...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238399/ https://www.ncbi.nlm.nih.gov/pubmed/37268749 http://dx.doi.org/10.1038/s41598-023-33153-8 |
_version_ | 1785053284176756736 |
---|---|
author | Zhan, Yixiang Ni, Kemin Liu, Zhaoce xin, Ran Han, Qiurong Ping, Hangyu Liu, Yaohong Zhao, Xuanzhu Wang, Wanting Yan, Suying Sun, Jing Zhang, Qinghuai Wang, Guihua Zhang, Zili Zhang, Xipeng Hu, Xia Li, Guoxun Zhang, Chunze |
author_facet | Zhan, Yixiang Ni, Kemin Liu, Zhaoce xin, Ran Han, Qiurong Ping, Hangyu Liu, Yaohong Zhao, Xuanzhu Wang, Wanting Yan, Suying Sun, Jing Zhang, Qinghuai Wang, Guihua Zhang, Zili Zhang, Xipeng Hu, Xia Li, Guoxun Zhang, Chunze |
author_sort | Zhan, Yixiang |
collection | PubMed |
description | We evaluate the prognostic value of chemotherapy and other prognostic factors on overall survival among colon patients with deficient mismatch repair (dMMR), and determine the optimum time to start chemotherapy after surgery. Data of 306 colon cancer patients with dMMR who received radical surgery were collected from three Chinese centers between August 2012 and January 2018. Overall survival (OS) was assessed with the Kaplan–Meier method and log-rank. Cox regression analysis were used to assess influencing prognosis factors. The median follow-up time for all patients was 45.0 months (range, 1.0–100). There was a nonsignificant OS benefit from chemotherapy for patients with stage I and stage II disease, including high-risk stage II disease (log-rank p: 0.386, 0.779, 0.921), and a significant OS benefit for patients with stage III and stage IV disease for receiving post-operation chemotherapy (log-rank p = 0.002, 0.019). Stage III patients benefitted from chemotherapy regimens that contained oxaliplatin (log-rank p = 0.004), and Starting chemotherapy with oxaliplatin treatment earlier resulted in better outcomes (95% CI 0.013–0.857; p = 0.035). Chemotherapy regimens containing oxaliplatin can prolong the survival time of stage III and IV dMMR colon cancer patients. This beneficial manifestation was more pronounced after starting chemotherapy treatment early post operation. High risk stage II dMMR colon patients including T(4)N(0)M(0) cannot benefit from chemotherapy. |
format | Online Article Text |
id | pubmed-10238399 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-102383992023-06-04 Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen Zhan, Yixiang Ni, Kemin Liu, Zhaoce xin, Ran Han, Qiurong Ping, Hangyu Liu, Yaohong Zhao, Xuanzhu Wang, Wanting Yan, Suying Sun, Jing Zhang, Qinghuai Wang, Guihua Zhang, Zili Zhang, Xipeng Hu, Xia Li, Guoxun Zhang, Chunze Sci Rep Article We evaluate the prognostic value of chemotherapy and other prognostic factors on overall survival among colon patients with deficient mismatch repair (dMMR), and determine the optimum time to start chemotherapy after surgery. Data of 306 colon cancer patients with dMMR who received radical surgery were collected from three Chinese centers between August 2012 and January 2018. Overall survival (OS) was assessed with the Kaplan–Meier method and log-rank. Cox regression analysis were used to assess influencing prognosis factors. The median follow-up time for all patients was 45.0 months (range, 1.0–100). There was a nonsignificant OS benefit from chemotherapy for patients with stage I and stage II disease, including high-risk stage II disease (log-rank p: 0.386, 0.779, 0.921), and a significant OS benefit for patients with stage III and stage IV disease for receiving post-operation chemotherapy (log-rank p = 0.002, 0.019). Stage III patients benefitted from chemotherapy regimens that contained oxaliplatin (log-rank p = 0.004), and Starting chemotherapy with oxaliplatin treatment earlier resulted in better outcomes (95% CI 0.013–0.857; p = 0.035). Chemotherapy regimens containing oxaliplatin can prolong the survival time of stage III and IV dMMR colon cancer patients. This beneficial manifestation was more pronounced after starting chemotherapy treatment early post operation. High risk stage II dMMR colon patients including T(4)N(0)M(0) cannot benefit from chemotherapy. Nature Publishing Group UK 2023-06-02 /pmc/articles/PMC10238399/ /pubmed/37268749 http://dx.doi.org/10.1038/s41598-023-33153-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Zhan, Yixiang Ni, Kemin Liu, Zhaoce xin, Ran Han, Qiurong Ping, Hangyu Liu, Yaohong Zhao, Xuanzhu Wang, Wanting Yan, Suying Sun, Jing Zhang, Qinghuai Wang, Guihua Zhang, Zili Zhang, Xipeng Hu, Xia Li, Guoxun Zhang, Chunze Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen |
title | Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen |
title_full | Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen |
title_fullStr | Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen |
title_full_unstemmed | Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen |
title_short | Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen |
title_sort | stage iii deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238399/ https://www.ncbi.nlm.nih.gov/pubmed/37268749 http://dx.doi.org/10.1038/s41598-023-33153-8 |
work_keys_str_mv | AT zhanyixiang stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen AT nikemin stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen AT liuzhaoce stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen AT xinran stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen AT hanqiurong stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen AT pinghangyu stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen AT liuyaohong stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen AT zhaoxuanzhu stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen AT wangwanting stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen AT yansuying stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen AT sunjing stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen AT zhangqinghuai stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen AT wangguihua stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen AT zhangzili stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen AT zhangxipeng stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen AT huxia stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen AT liguoxun stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen AT zhangchunze stageiiideficientmismatchrepaircolonpatientsgetgreaterbenefitfromearlierstartingoxaliplatinbasedchemotherapyregimen |